ENTRY       D10847                      Drug
NAME        Epoetin zeta (INN);
            Retacrit (TN);
            Silapo (TN)
FORMULA     C809H1301N229O240S5
EXACT_MASS  18224.5242
MOL_WEIGHT  18235.7015
SEQUENCE    APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA WKRMEVGQQA
            VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS
            PPDAASAAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA CRTGD
            (Disulfide bridge: 7-161, 29-33)
  TYPE      Peptide
REMARK      ATC code: B03XA01
            Chemical structure group: DG00177
            Product (DG00177): D03231<JP/US> D03232<JP>
EFFICACY    Anti-anemic, Antineoplastic
TARGET      EPOR [HSA:2057] [KO:K05079]
  PATHWAY   hsa04060(2057)  Cytokine-cytokine receptor interaction
            hsa04630(2057)  JAK-STAT signaling pathway
            hsa04640(2057)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B03 ANTIANEMIC PREPARATIONS
               B03X OTHER ANTIANEMIC PREPARATIONS
                B03XA Other antianemic preparations
                 B03XA01 Erythropoietin
                  D10847  Epoetin zeta (INN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               CSF and other factor receptors
                EPOR
                 D10847  Epoetin zeta (INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10847
DBLINKS     CAS: 604802-70-2
            PubChem: 319902647
///
